Podcasts about Moderna

──────────────────────────────────── 00:00:51:15 — Directed Energy Weapons Move From Theory to BattlefieldAutonomous killer systems and microwave weapons are described as transitioning from speculation into active military doctrine. ──────────────────────────────────── 00:07:44:24 — Intelligence Agencies Downplayed Directed Energy CapabilitiesInternal awareness of microwave weapon effects is contrasted with public minimization of their existence. ──────────────────────────────────── 00:14:59:19 — Hypersonic Missiles Undermine “Golden Dome” DefenseAdvanced missile systems are cited as rendering proposed U.S. missile shields technologically and financially unrealistic. ──────────────────────────────────── 00:21:12:01 — Federal Agents Escalate Use of Crowd-Control WeaponsTear gas, flash bangs, and rubber bullets are reportedly deployed broadly against protesters and bystanders. ──────────────────────────────────── 00:29:13:09 — Body Cam Footage Captures Aggressive Use-of-Force DirectiveA supervisor's recorded comments raise concerns about normalization of escalatory force tactics. ──────────────────────────────────── 00:35:48:25 — Federal Immunity Shields Officers From AccountabilityBroad immunity claims collide with court findings noting repeated excessive-force violations. ──────────────────────────────────── 01:04:52:09 — FDA Blocks New mRNA Flu ShotRegulators halt advancement of a Moderna flu vaccine, breaking with expectations of streamlined approval. ──────────────────────────────────── 01:18:50:21 — Vaccines Framed as National Security InfrastructureGlobal health leaders argue vaccine production should operate as centralized state security architecture. ──────────────────────────────────── 01:23:54:27 — Pandemic Policies Normalize Permanent Emergency PowersMandates, liability shields, and censorship are portrayed as embedded tools of governance beyond crisis conditions. ──────────────────────────────────── 01:24:17:13 — Legislative Push to End Vaccine Manufacturer ImmunityNew legislation challenges longstanding liability protections for pharmaceutical companies. ──────────────────────────────────── 01:43:14:10 — Third-Term Discussion Challenges Constitutional LimitsPublic talk of bypassing the 22nd Amendment is framed as normalization of executive permanence. ──────────────────────────────────── 01:55:48:12 — Convicted Elites Rebrand Through Alternative MediaDisgraced figures leverage online platforms to rebuild public narratives and pressure for clemency. ──────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

The U.S. Food and Drug Administration announced recently that it will not review Moderna's mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and outside the industry concerned about the Trump administration's approach to vaccine development and recommendations. Amna Nawaz discussed more with Michael Osterholm. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

──────────────────────────────────── 00:00:51:15 — Directed Energy Weapons Move From Theory to BattlefieldAutonomous killer systems and microwave weapons are described as transitioning from speculation into active military doctrine. ──────────────────────────────────── 00:07:44:24 — Intelligence Agencies Downplayed Directed Energy CapabilitiesInternal awareness of microwave weapon effects is contrasted with public minimization of their existence. ──────────────────────────────────── 00:14:59:19 — Hypersonic Missiles Undermine “Golden Dome” DefenseAdvanced missile systems are cited as rendering proposed U.S. missile shields technologically and financially unrealistic. ──────────────────────────────────── 00:21:12:01 — Federal Agents Escalate Use of Crowd-Control WeaponsTear gas, flash bangs, and rubber bullets are reportedly deployed broadly against protesters and bystanders. ──────────────────────────────────── 00:29:13:09 — Body Cam Footage Captures Aggressive Use-of-Force DirectiveA supervisor's recorded comments raise concerns about normalization of escalatory force tactics. ──────────────────────────────────── 00:35:48:25 — Federal Immunity Shields Officers From AccountabilityBroad immunity claims collide with court findings noting repeated excessive-force violations. ──────────────────────────────────── 01:04:52:09 — FDA Blocks New mRNA Flu ShotRegulators halt advancement of a Moderna flu vaccine, breaking with expectations of streamlined approval. ──────────────────────────────────── 01:18:50:21 — Vaccines Framed as National Security InfrastructureGlobal health leaders argue vaccine production should operate as centralized state security architecture. ──────────────────────────────────── 01:23:54:27 — Pandemic Policies Normalize Permanent Emergency PowersMandates, liability shields, and censorship are portrayed as embedded tools of governance beyond crisis conditions. ──────────────────────────────────── 01:24:17:13 — Legislative Push to End Vaccine Manufacturer ImmunityNew legislation challenges longstanding liability protections for pharmaceutical companies. ──────────────────────────────────── 01:43:14:10 — Third-Term Discussion Challenges Constitutional LimitsPublic talk of bypassing the 22nd Amendment is framed as normalization of executive permanence. ──────────────────────────────────── 01:55:48:12 — Convicted Elites Rebrand Through Alternative MediaDisgraced figures leverage online platforms to rebuild public narratives and pressure for clemency. ──────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving grounds. On the latest BioCentury This Week podcast, BioCentury's Lauren Martz assesses how the oral SERD landscape is evolving.Washington Editor Steve Usdin then discusses setbacks at FDA for an orphan therapy from Disc Medicine and a vaccine from Moderna, and why he is calling on life sciences industry leaders to publicly demand the dismissal of Vinay Prasad, FDA's CSO, CMO, and director of CBER.View full story: https://www.biocentury.com/article/658455#TargetedProteinDegradation #OralSERDs #OncologyDrugDevelopment #FDASetbacks #CBER00:00 - Introduction03:12 - Oral SERD Spotlight11:40 - Setbacks at FDA15:12 - Disc Medicine CRLTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and decisions in the industry that are shaping the path forward for drug development and patient care.The U.S. Food and Drug Administration (FDA), an agency often at the center of pharmaceutical innovation and scrutiny, has recently made several noteworthy decisions. These decisions not only point to the ongoing regulatory challenges but also highlight scientific advancements within the field.One of the key updates involves the FDA's decision to reject Disc's drug bitopertin, which was intended for the treatment of erythropoietic protoporphyria, a rare blood disease. Despite receiving a national priority voucher for expedited review, the FDA ultimately concluded that the clinical data did not sufficiently support regulatory approval. This decision underscores the FDA's commitment to maintaining rigorous standards even when expedited reviews are in play, emphasizing the necessity of robust clinical evidence for approval.Adding complexity to this situation is the internal dynamics within the FDA itself. Richard Pazdur, a long-standing official at the agency, recently stepped down, revealing disagreements with Commissioner Marty Makary over reducing the number of clinical trials required for new drug applications. Pazdur's departure after an influential 26-year tenure highlights ongoing debates within regulatory bodies on how to balance innovative approval pathways with ensuring safety and efficacy data.In another notable development, Moderna faced setbacks with its mRNA-1010 flu vaccine as the FDA declined to review it. This decision leaves American consumers without access to potentially more effective mRNA-based flu vaccines—a technology embraced by other countries for influenza treatment. This situation points to possible missed opportunities in leveraging cutting-edge vaccine technologies domestically, showcasing both the promise and regulatory complexities surrounding mRNA technology.These regulatory challenges unfold amid leadership changes and strategic shifts within health agencies. For instance, Jim O'Neill's departure from his role as acting director of the Centers for Disease Control and Prevention following Susan Monarez's abrupt ouster illustrates how leadership turbulence can impact policy consistency and strategic direction, potentially affecting how new health initiatives are prioritized and implemented.Meanwhile, companies like Vertex and CRISPR Therapeutics are ambitiously advancing gene therapy solutions such as Casgevy, signaling a broader trend towards personalized medicine and advanced biotechnological approaches. These efforts promise transformative impacts on patient care and reflect an industry-wide move towards precision medicine.Eli Lilly's substantial investment in orforglipron stock ahead of its anticipated approval further indicates confidence in their product pipeline amidst growing competition from Novo Nordisk's Wegovy pill abroad. This competitive landscape highlights increasing interest and investment in innovative treatments for metabolic diseases.Overall, these developments illustrate a dynamic interplay between scientific innovation, regulatory scrutiny, and strategic corporate maneuvers that shape healthcare's future. As companies push technological boundaries, regulators face ongoing challenges in adapting frameworks that ensure patient safety while fostering innovation. The outcomes of these processes will significantly influence not only patient access to cutting-edge therapies but also set precedents for future drug development and approval pathways. As these trends unfold, stakeholders across the industry must remain agile, informed, and collaborative to navigate this evolving landscape effectively.Looking back at 2025, it was a tSupport the show

TODAY ON THE ROBERT SCOTT BELL SHOW: MAHA Boosts GOP Momentum, Dr. Stephen Sanders, Whole Mens Health, FDA Blocks Moderna Jab, Dr. Robert Thompson, Mary Kay Stenger, Mineral Medicine Breakthrough, Alfalfa, Medical Freedom Act, and MORE! https://robertscottbell.com/maha-boosts-gop-momentum-dr-sanders-mens-health-fda-blocks-moderna-dr-robert-thompson-aurora-health-mary-kay-stenger-mineral-medicine-breakthrough-alfalfa-medical-freedom-act-and-more/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Chuck Todd takes a hard look at the state of American governance and institutional trust — or the lack of it. He starts by reflecting on the historical significance of three consecutive one-term presidents, ranking his top five most underrated commanders-in-chief and arguing that both Biden and Trump are unlikely to be viewed as consequential a century from now. From there, Todd pivots to a searing indictment of the current moment: from the Epstein reckoning exposing the government's inability to tell the truth, to DHS being treated as a political plaything by Kristi Noem and Corey Lewandowski, to the DOD endangering lives in the El Paso FAA incident with zero accountability, to Moderna alleging that HHS refused to even review an mRNA flu vaccine under RFK Jr.'s watch. He connects the dots across a pattern of institutional dishonesty — a Justice Department focused on narrative management, masked ICE agents no one can justify, a fired antitrust chief clearing the way for powerful interests, and a "hostage system" style of governing that holds federal paychecks as leverage — making the case that when the government lies this often, it forfeits the benefit of the doubt on everything, and that the Epstein scandal isn't just a story about one man, but a mirror reflecting a system designed to protect the powerful. Finally, Chuck hops into the ToddCast Time Machine to revisit the publishing of the Communist Manifesto and argues that while its critiques of the excesses of capitalism were correct… it’s revolutionary prescriptions led to the worst authoritarian states in modern history. He also answers listeners’ questions in the “Ask Chuck” segment. Get your wardrobe sorted and your gift list handled with Quince. Don't wait! Go to https://Quince.com/CHUCK for free shipping on your order and 365-day returns. Now available in Canada, too! Protect your family with life insurance from Ethos. Get up to $3 million in coverage in as little as 10 minutes at https://ethos.com/chuck. Application times may vary. Rates may vary. Thank you Wildgrain for sponsoring. Visit http://wildgrain.com/TODDCAST and use the code "TODDCAST" at checkout to receive $30 off your first box PLUS free Croissants for life! Link in bio or go to https://getsoul.com & enter code TODDCAST for 30% off your first order. Timeline: (Timestamps may vary based on advertisements) 00:00 Chuck Todd’s introduction 02:30 We’ve had 3 straight one term presidents, deem them all failures 03:45 Inability to win reelection will always be seen as an asterisk 04:45 Top 5 most underrated presidents 05:00 James Polk was the only voluntary one term president 05:45 James Garfield was a fierce advocate for civil rights 06:30 George H.W. Bush was accomplished, but not a good politician 07:30 John Quincy Adams laid out modern American infrastructure 08:00 Jimmy Carter did many things that have aged well 09:15 In 100 years, Biden & Trump likely won’t be viewed as consequential 10:45 Biden & Trump can’t be evaluated fairly for many years 11:30 What does a real reckoning look like in the Trump era? 12:45 The institution least capable of reckoning with Epstein is the government 13:15 The private sector is forcing accountability, the government isn’t 14:15 Trust is the currency of government, and Trump’s doesn’t have it 15:15 The Justice Department is only worried about narrative management 16:30 The system looks like a club, designed to protect the powerful 17:45 Epstein is a test of whether the government can tell the truth 19:00 DHS shutting down, politicians using paychecks as leverage 19:30 We a governing via a “hostage system” 20:45 There isn’t a single good argument for masking ICE agents 21:15 The Democrats’ demands are not extreme, they’re common sense 22:15 Noem & Lewandowski treating DHS like their personal plaything 23:00 Pattern of government saying one thing, facts saying another 24:15 Whatever Noem says first, you can’t believe it. She gaslights the public 25:00 The government has lied too many times, gets no benefit of the doubt 25:45 El Paso FAA incident is case study for public distrusting institutions 26:45 DoD was lying to the FAA, FAA pulled the emergency brakes 28:00 DoD put lives in danger with no accountability 28:30 Moderna says HHS refused to review MRNA flu vaccine 29:15 The U.S. is not a stable country to develop & release products 30:00 Kennedy only offers crackpot theories & totally unfit for office 31:00 We can’t trust the government to tell us the truth about anything 31:30 DOJ fired antitrust chief, powerful interests get what they want 33:00 Epstein isn’t just a scandal, it’s a mirror 42:15 What if Ro Khanna and Thomas Massie ran on “accountability” ticket 43:30 A bipartisan ticket of “pox on both their houses” could be powerful 44:15 ToddCast Time Machine February 21st, 1848 44:30 Marx & Engels publish the communist manifesto 45:15 Monarchies were colliding with modern economic forces 46:45 Marx argued that capitalism is destabilizing if left unchecked 47:45 If the manifesto was called something else, how would we view it? 48:15 Marx doesn’t argue reform, says that capitalism will destroy itself 49:00 Communist states didn’t emerge until decades after manifesto 49:45 Manifesto gave dictators arguments to grab power 50:30 Marx talked in economics, dictators exploited his language 52:00 Communism took hold in places where industrialization fell behind 52:45 Manifesto gets invoked badly by both sides in American politics 53:30 Marx’s diagnosis was spot on, his solutions were questionable 55:00 Lack of regulation for AI will push people to radicalism 55:30 Ask Chuck 55:45 Does something seem off with the administration’s economic numbers? 1:00:00 Do we need a punchier title than “Gate” for political scandals? 1:02:30 Do we need to withhold congressional salaries during shutdowns? 1:06:30 Missing intellectuals like Rahm Emmanuel leading the country 1:08:30 What is the criteria for impeachment of cabinet members? 1:11:15 Favorite football/baseball players as a kid?See omnystudio.com/listener for privacy information.

Chuck Todd takes a hard look at the state of American governance and institutional trust — or the lack of it. He starts by reflecting on the historical significance of three consecutive one-term presidents, ranking his top five most underrated commanders-in-chief and arguing that both Biden and Trump are unlikely to be viewed as consequential a century from now. From there, Todd pivots to a searing indictment of the current moment: from the Epstein reckoning exposing the government's inability to tell the truth, to DHS being treated as a political plaything by Kristi Noem and Corey Lewandowski, to the DOD endangering lives in the El Paso FAA incident with zero accountability, to Moderna alleging that HHS refused to even review an mRNA flu vaccine under RFK Jr.'s watch. He connects the dots across a pattern of institutional dishonesty — a Justice Department focused on narrative management, masked ICE agents no one can justify, a fired antitrust chief clearing the way for powerful interests, and a "hostage system" style of governing that holds federal paychecks as leverage — making the case that when the government lies this often, it forfeits the benefit of the doubt on everything, and that the Epstein scandal isn't just a story about one man, but a mirror reflecting a system designed to protect the powerful. Then, Gene Sperling — the only person to serve as Director of the National Economic Council under two presidents (Clinton and Obama), a senior advisor to President Biden who oversaw the American Rescue Plan, and a consultant and co-writer on NBC's The West Wing — joins the Chuck Toddcast for a wide-ranging conversation. Sperling shares the wild story of how he ended up in Santa Monica, his brush with Aaron Sorkin's legal troubles, and his insider take on how real Washington compares to its fictional portrayals. The conversation then turns to Sperling's deep expertise on the economy, from his defense of the Biden administration's "soft landing" amid global post-Covid inflation to the political lessons of how rising prices have sunk presidencies on both sides of the aisle — including Biden's own re-election bid. The back half of the episode looks squarely at the future. Sperling, who says he's unlikely to serve in another Democratic administration, offers a forceful argument about what comes next: the rising threat of unchecked corporate and tech power, the urgent need for AI policy that puts working people first, and the lessons of globalization that policymakers can't afford to repeat. Drawing on themes from his book Economic Dignity, he makes the case that Americans are hungry for leaders who pair optimism with a real confrontation of economic injustice — and warns that a handful of AI and crypto companies, flush with lobbying dollars, could end up shaping the structure of the economy if left unchallenged. Finally, Chuck hops into the ToddCast Time Machine to revisit the publishing of the Communist Manifesto and argues that while its critiques of the excesses of capitalism were correct… it’s revolutionary prescriptions led to the worst authoritarian states in modern history. He also answers listeners’ questions in the “Ask Chuck” segment. Get your wardrobe sorted and your gift list handled with Quince. Don't wait! Go to https://Quince.com/CHUCK for free shipping on your order and 365-day returns. Now available in Canada, too! Protect your family with life insurance from Ethos. Get up to $3 million in coverage in as little as 10 minutes at https://ethos.com/chuck. Application times may vary. Rates may vary. Thank you Wildgrain for sponsoring. Visit http://wildgrain.com/TODDCAST and use the code "TODDCAST" at checkout to receive $30 off your first box PLUS free Croissants for life! Link in bio or go to https://getsoul.com & enter code TODDCAST for 30% off your first order. Timeline: (Timestamps may vary based on advertisements) 00:00 Chuck Todd’s introduction 03:30 We’ve had 3 straight one term presidents, deem them all failures 04:45 Inability to win reelection will always be seen as an asterisk 05:45 Top 5 most underrated presidents 06:00 James Polk was the only voluntary one term president 06:45 James Garfield was a fierce advocate for civil rights 07:30 George H.W. Bush was accomplished, but not a good politician 08:30 John Quincy Adams laid out modern American infrastructure 09:00 Jimmy Carter did many things that have aged well 10:15 In 100 years, Biden & Trump likely won’t be viewed as consequential 11:45 Biden & Trump can’t be evaluated fairly for many years 12:30 What does a real reckoning look like in the Trump era? 13:45 The institution least capable of reckoning with Epstein is the government 14:15 The private sector is forcing accountability, the government isn’t 15:15 Trust is the currency of government, and Trump’s doesn’t have it 16:15 The Justice Department is only worried about narrative management 17:30 The system looks like a club, designed to protect the powerful 18:45 Epstein is a test of whether the government can tell the truth 20:00 DHS shutting down, politicians using paychecks as leverage 20:30 We a governing via a “hostage system” 21:45 There isn’t a single good argument for masking ICE agents 22:15 The Democrats’ demands are not extreme, they’re common sense 23:15 Noem & Lewandowski treating DHS like their personal plaything 24:00 Pattern of government saying one thing, facts saying another 25:15 Whatever Noem says first, you can’t believe it. She gaslights the public 26:00 The government has lied too many times, gets no benefit of the doubt 26:45 El Paso FAA incident is case study for public distrusting institutions 27:45 DoD was lying to the FAA, FAA pulled the emergency brakes 29:00 DoD put lives in danger with no accountability 29:30 Moderna says HHS refused to review MRNA flu vaccine 30:15 The U.S. is not a stable country to develop & release products 31:00 Kennedy only offers crackpot theories & totally unfit for office 32:00 We can’t trust the government to tell us the truth about anything 32:30 DOJ fired antitrust chief, powerful interests get what they want 34:00 Epstein isn’t just a scandal, it’s a mirror 43:30 Gene Sperling joins the Chuck Toddcast 45:30 The wild story of how Gene ended up in Santa Monica 46:45 Aaron Sorkin couldn’t meet with Gene due to legal trouble 49:45 Real politics/news look nothing like “West Wing” or “The Newsroom” 51:00 The one truism about the West Wing is good people trying to do good 52:45 Politics is NOT like House of Cards 54:15 West Wing still remains viable, any chance of a reboot? 55:30 What’s the state of the economy? What do you look for? 56:15 Biden economy was strong growth, but high inflation 57:00 Biden achieved the “soft landing” they were trying for 58:15 Inflation was global and mostly due to Covid supply chain shocks 59:45 The American Rescue Plan had many positive effects 1:00:45 Every head of state poured money into economies during Covid 1:01:45 Covid was going to result in either inflation or recession 1:03:30 Obama couldn’t pass enough stimulus during Great Recession 1:04:30 A little extra stimulus can help offset future unknowns 1:05:15 Millennials’ future was permanently damaged by Great Recession 1:06:30 A generation had never seen high inflation until Covid 1:07:30 Anger over inflation sunk Biden’s re-election 1:08:30 Inflation is bipartisan, took down 3 different presidents 1:09:30 Inflation affects everyone, jobs & unemployment don’t 1:10:45 Every head of state suffered politically post pandemic 1:12:45 Will Biden baggage sink Pete Buttigieg, or is that overstated? 1:14:30 Biden’s conflict was empathy for suffering vs touting achievements 1:16:45 Biden had the tiniest of margins to pass major legislation 1:18:00 Gene is unlikely to work in a future Democratic administration 1:18:45 Pitchforks are being sharpened for corporations and big tech 1:19:30 Will worker rage fuel the next election? 1:20:30 Presidents that do well offer optimism, but confront economic injustice 1:22:00 People don’t want to feel like they are being extracted for profits 1:24:00 AI growth can’t come at the expense of working people 1:25:30 AI policy should be shaped around improving conditions for people 1:26:45 What lessons from globalization can be used to alleviate AI disruption? 1:28:30 Clinton believed in robust response to globalization 1:29:30 Clinton couldn’t implement strong safety net after losing congress 1:31:15 You have to have policies where people don’t feel left behind 1:33:00 We need to create and fund jobs that create dignity 1:33:45 We need to create an economic dignity floor for all Americans 1:35:45 When is a company too big to regulate? 1:38:00 If companies are disproportionately determining policies, they’re too big 1:38:45 Crypto & AI are getting what they want from huge lobbying money 1:39:30 A handful of AI companies could determine structure of the economy 1:41:45 The Trump White House has invited corporate influence 1:49:45 What if Ro Khanna and Thomas Massie ran on “accountability” ticket 1:51:00 A bipartisan ticket of “pox on both their houses” could be powerful 1:51:45 ToddCast Time Machine February 21st, 1848 1:52:00 Marx & Engels publish the communist manifesto 1:52:45 Monarchies were colliding with modern economic forces 1:54:15 Marx argued that capitalism is destabilizing if left unchecked 1:55:15 If the manifesto was called something else, how would we view it? 1:55:45 Marx doesn’t argue reform, says that capitalism will destroy itself 1:56:30 Communist states didn’t emerge until decades after manifesto 1:57:15 Manifesto gave dictators arguments to grab power 1:58:00 Marx talked in economics, dictators exploited his language 1:59:30 Communism took hold in places where industrialization fell behind 2:00:15 Manifesto gets invoked badly by both sides in American politics 2:01:00 Marx’s diagnosis was spot on, his solutions were questionable 2:02:30 Lack of regulation for AI will push people to radicalism 2:03:00 Ask Chuck 2:03:15 Does something seem off with the administration’s economic numbers? 2:07:30 Do we need a punchier title than “Gate” for political scandals? 2:10:00 Do we need to withhold congressional salaries during shutdowns? 2:14:00 Missing intellectuals like Rahm Emmanuel leading the country 2:16:00 What is the criteria for impeachment of cabinet members? 2:18:45 Favorite football/baseball players as a kid?See omnystudio.com/listener for privacy information.

Aktien hören ist gut. Aktien kaufen ist noch besser. Unser Partner Scalable Capital ist jetzt Bank und bietet euch dadurch jetzt noch bessere Konditionen. Mehr Infos findet ihr unter: scalable.capital/oaws. Pinterest zeigt: Meta geht's gut. Coinbase zeigt: Instis sind stabil. Rivian zeigt: E-Autowachstum ist möglich. Außerdem gibt's Zahlen von Roku und Moderna. Und Sumitomo Forestry baut Häuser für Amis mit Tri Pointe Homes. Stecken wir in einem der krassesten Rohstoff-Superzyklen ever? Jeff Currie sagt: Ja. Airbnb (WKN: A2QG35) oder Expedia (WKN: A1JRLJ) - wer wird mehr von KI bedroht? Und was hat Walmart damit zu tun? Diesen Podcast vom 16.02.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events shaping the landscape of drug development, regulatory scrutiny, and industry advancement. As we navigate this complex terrain, we'll explore how these changes impact both companies and patients.In recent news, Moderna has encountered a substantial hurdle as the FDA declined to review its flu vaccine candidate, mRNA-1010. This decision marks a notable shift from the expedited processes witnessed during the COVID-19 pandemic, reflecting a more cautious regulatory approach under current administrative leadership. Analysts suggest this could indicate broader regulatory changes that might affect future vaccine approvals. Moderna's situation is emblematic of the challenges companies face in maintaining momentum post-pandemic, especially as their research and development spending saw a significant decrease of 31% last year due to completed respiratory trials. This reduction highlights a strategic pivot as the company reassesses its priorities amidst an evolving market landscape.Vertex Pharmaceuticals is making headlines with its ambitious revenue goals outside its established cystic fibrosis franchise. By 2026, Vertex aims to generate $500 million from non-CF medications, with recent launches like Casgevy and Journavx already showing promise by collectively bringing in $175.6 million last year. This diversification strategy is critical for mitigating risks associated with dependence on a single therapeutic area and reflects a broader industry trend towards strategic realignment. Additionally, Vertex remains under close observation within kidney disease portfolios, particularly with Povetacicept—an IgA nephropathy treatment—and the success of Journavx impacting market positions by offering chronic kidney disease patients new therapeutic options.PTC Therapeutics has faced setbacks with its FDA application withdrawal for Translarna, intended for treating nonsense mutation Duchenne muscular dystrophy. The decision came after receiving adverse feedback from the FDA, highlighting the complexities involved in gaining approval for therapies targeting intricate genetic conditions. Such hurdles underscore the high-risk nature of biotech ventures that are heavily reliant on regulatory timelines.Novartis is pushing forward with plans to seek full FDA approval for Vanrafia, its IgA nephropathy drug, despite not meeting primary kidney function goals in Phase 3 trials. This move aligns with a growing trend where companies pursue approval based on secondary endpoints or other supportive data when primary outcomes fall short. Such strategies underscore the competitive and high-stakes environment surrounding drug approval pathways.Novo Nordisk is expanding its production capabilities in Ireland to meet increasing demand for Wegovy, their obesity drug that's seen impressive sales in the U.S. This investment underscores the global potential for obesity treatments and highlights how manufacturing expansions are pivotal to supporting international market entry.In Europe, Amgen has secured approval for Uplizna in treating myasthenia gravis, adding another option to an already crowded treatment landscape but offering patients additional therapeutic choices. Meanwhile, AbbVie has launched a legal challenge against Botox's inclusion in drug pricing negotiations under the Inflation Reduction Act (IRA), arguing it should be excluded due to its plasma-derived nature.Ultragenyx has announced a 10% workforce reduction amid halted gene therapy plans and unsuccessful late-stage trials in brittle bone disease. These adjustments often reflect broader strategic shifts within biopharma companies as they realign focus and resources. Ultragenyx's operational challenges highlight the volatile nature of biotech ventureSupport the show

El historiador Ismael López analiza en el libro ‘Sables al viento' el último siglo de vida de la guerra a caballo

TWiV explains the observation that filamentous virions act as non-infectious interfering particles to modulate papillomavirus infection, and transmission of monkeypox virus from fire-footed rope squirrels to sooty mangabeys. Hosts: Vincent Racaniello, Alan Dove, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Positions in Rosenfeld Lab (email) FDA refuses to review Moderna flu mRNA vaccine (CIDRAP) Oz measles vaccine call, too little too late? (dw.com) Defective human papillomavirus interfering virus particles (J Virol) Fire-footed rope squirrel potential MPXV reservoir (Nature) Squirrels could be MPXV reservoir (Nature) Letters read on TWiV 1297 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – Silo TV series Kathy – Ancient RNA expression profiles from the extinct woolly mammoth and Ancient host-associated microbes obtained from mammoth remains Alan – Ubik, by Philip K. Dick Vincent – Starry Messenger by Neil deGrasse Tyson Listener Pick Beth – Iceland crime fiction authors Yrsa Sigurdardottir and Ragnar Jonasson Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

Técnicamente los ciudadanos de Puerto Rico son ciudadanos norteamericanos pero no tienen derecho a votar por los líderes norteamericanos que toman decisiones por su territorio. Cuando la isla ha sido azotada por algún desastre natural tienen fallas terribles de infrastructura y han quedado prácticamente en el abandono. Puerto Rico es una colonia moderna y hoy en Herejes el podcast de contamos su historia e intentamos entender los eventos históricos que produjeron las circunstancias actuales. 2026 es el año de Herejes en Patreon. Mucho más contenido exclusivo creado por todos los Herejes, Larva, y Caro H Solis. Suscríbete y nos ayudas como de ninguna otra forma https://www.patreon.com/herejeselpodcast Merch https://chunchos.mx/collections/herejes - Ale Durán - https://www.instagram.com/corsario.hereje/ - Vasco - https://instagram.com/vasco.hereje/ - @BobbyHereje - https://www.instagram.com/bobby.hereje Learn more about your ad choices. Visit megaphone.fm/adchoices

As portas dos automóveis modernos, denominadas “tipo Tesla”, são controladas electronicamente e, durante um acidente grave — ou inundação — em que o carro fique sem bateria, são impossíveis de abrir.See omnystudio.com/listener for privacy information.

We get the latest from the Munich Security Conference, where U.S. Secretary of State Marco Rubio delivered a speech before European leaders. We also look at the reasons behind why the FDA rejected Moderna's new flu vaccine and how that decision could shape future clinical trials. Plus, we'll look at the what happened with U.S Olympic figure skater Illia Malinin, dubbed the "Quad God," on the ice yesterday. Tipped to win the gold, Malinin didn't end up even medaling. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In his weekly clinical update, Dr. Griffin and Vincent Racaniello are shocked by recent events, including Dr. Oz's appeal for measles vaccination, Vinjay Prasad's unilateral rejection of Moderna's mRNA influenza vaccine application, and the increasing number of New World screw worm cases, then Dr. Griffin then deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, where to find PEMGARDA, how to access and pay for Paxlovid, the number of measles deaths in Mexico, long COVID treatment center, where to go for answers to your long COVID questions, choroid plexus alterations in long COVID association with neuropathologies and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode How Dr. Oz's appeal to get measles vaccine may differ from RFK Jr.'s messaging (ABC News) FDA reverses course, refuses to review Moderna's application for new mRNA flu vaccine (CIDRAP) Hepatitis B Vaccination at Birth: Safety, Effectiveness, and Public Health Benefit (American Academy of Pediatrics: Pediatrics) US Olympic Committee remains 'dialed in' to prevent spread of stomach illness at Winter Games (CNN) Oz promotes measles vaccination (NY Times; USA Today; Fortune) Screw worm in Mexico (Gobierno de Mexico) Mexico reports more human New World screwworm infections (CIDRAP) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Measles outbreak poses risk of 'irreversible' brain damage, health officials warn (Fox News) In Mexico, at least 28 have died from measles outbreak that started 2025 (Reuters) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) USrespiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) Influenza vaccination and the risk of myocardial infarction(BMC Publich Health) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-world global database (Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Choroid plexus alterations in long COVID and their associations with Alzheimer's disease risks (Alzheimer's & Dementia) Reaching out to US house representative Letters read on TWiV 1296 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

This Valentine's Day, we invite you to step into one of the most extraordinary love stories in contemporary art — a story where passion became performance and devotion became artistic legacy. In this intimate and thought-provoking episode of Feel Slovenia the podcast, we explore the powerful intersection of love, risk and radical creativity.At its heart is Art Vital, the landmark exhibition at Cukrarna in Ljubljana, which traces the groundbreaking collaborative work of Marina Abramović and Ulay, who were partners in life as much as in art — living nomadically in a van, placing absolute trust in one another and testing the limits of endurance, vulnerability and connection. In this deeply personal conversation, Marina Abramović, arguably the world's most famous living artist, reflects on how they met, how their creative alliance took shape, and what it meant to make art at a time when performance had no market, no clear institutional support and no safety net. What drove them forward was a shared vision — radical, uncompromising and profoundly human.The episode also illuminates Slovenia's vibrant contemporary art landscape — from Moderna galerija and the Museum of Contemporary Art Metelkova in Ljubljana to the forthcoming museum in Bled — underscoring the country's growing role as a compelling cultural destination in Europe.Feel Slovenia the Podcast is brought to you by the Slovenian Tourist Board and hosted by Dr Noah Charney.Sound Production: Urska Charney For more inspirational content, check out www.slovenia.info and our social media channels, including Instagram, Facebook, YouTube, Twitter, Pinterest, LinkedIn and Tripadvisor.

Carl Quintanilla, Courtney Reagan, and Michael Santoli capped off a big week of volatility and earnings with a panel of market veterans: Moody's Mark Zandi and former Leuthold Group CIO Jim Paulsen, before a deep-dive into 2 of the morning's biggest reports - Airbnb & Roku, with the CEOs of both companies. Hear how Roku is bullish on AI's opportunity to drive down costs - and why the CEO of Airbnb says his company's built to ride the disruption.  Plus: more on the day's biggest earnings reports - spanning Moderna's big earnings beat driving shares higher, to the tariff headwind slamming Pinterest shares.  Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the US Food and Drug Administration's controversial decision to refuse to file Moderna's mRNA-1010 seasonal influenza vaccine candidate, including the unusual public airing of grievances (2:10), the changing issues sparking RTF actions (5:51), the uncertainty created by the decision and how vaccine sponsors should react going forward (16:54). More On These Topics From The Pink Sheet Moderna Cites Changing Advice As US FDA Refuses To File Flu Vaccine BLA: https://insights.citeline.com/pink-sheet/vaccines/moderna-cites-changing-advice-as-us-fda-refuses-to-file-flu-vaccine-bla-SRLIEHHMOFEWFPTLYJCXFIF5FM/ HHS Defends US FDA Refusal To File Moderna's Flu Vaccine: https://insights.citeline.com/pink-sheet/vaccines/hhs-defends-us-fda-refusal-to-file-modernas-flu-vaccine-NULTQ6P6R5C6DDXZFMZROE3HRU/

Disclosures:Dr. Creech has disclosures of grant funding from NIH, CDC, Moderna, Pfizer and has been a consultant for Merck, Sanofi Paseur, TD. Cowen. Guidepoint Global, GSK, Delbiopharm, Dianthus, AstraZenecka and receives royalties from UpToDateWebsites:Philadelphia Children's Hospital Vaccine Education & ResourcesVUMC Children's Immunization GuideAAPRecommended Books:Anxious Generation: How The Great Rewiring of Childhood Is Causing an Epidemic of Mental Illness, Jonathan HaidtRighteous Mind: Why Good People Are Divided by Politics and Religion, Jonathan HaidtKey TakeawaysRSV prevention now includes both maternal vaccination during third trimester and monoclonal antibodies for infants, both showing 60-80% reduction in hospitalizationsHepatitis B vaccine is fundamentally a cancer prevention tool, and the birth dose is recommended at population level to prevent missed cases even when individual risk appears lowCocooning newborns through family immunization for influenza, pertussis, RSV, and measles is critical as community vaccination rates declineEffective vaccine conversations require avoiding shame and blame, expressing intellectual humility, asking "why" to understand concerns, and providing trusted resources rather than just educationThe future of vaccine development includes improved flu vaccines requiring less frequent administration, alternative delivery methods (intranasal, oral, microneedles), and advanced tools to understand rare adverse eventsWhile vaccine-preventable diseases like measles are increasing in pockets of under-vaccinated communities, maintaining high vaccination rates is essential to prevent widespread outbreaks of highly contagious diseasesParents face significant peer pressure around vaccine decisions, and healthcare providers should acknowledge this while modeling respectful dialogue with those who disagreeQuotable Moments"What is hepatitis B vaccine? It's a cancer prevention vaccine period. It prevents liver cancer. Why would I not want a cancer preventing vaccine?""An ounce of prevention is worth a pound of cure rather than knowing how to treat meningitis really effectively. Wouldn't it be great if we could prevent it all together?""I think we need to recognize that we probably want the same thing, except in extraordinarily weird situations. We both want the health of that child.""I recognize that there is still much to learn about these things, but here's where I land.""Vaccines and your baby's health, that's just more complicated than 140 characters.""Measles is the second most contagious virus on the planet behind smallpox, which is eradicated. So it's the first most...

US President Trump plans to roll back tariffs on metal and aluminium goods, according to FT.European equities shrug off the selloff seen stateside; Tech rebounds while Basic Resources lag; US equity futures hold steady.DXY slightly firmer and USTs rangebound heading into US CPI; JPY underperforms.Precious metals recover following Thursday's slump, whilst Copper lags on the back of weaker risk sentiment; Crude flat.Looking ahead, highlights include US CPI (Jan), Speakers including ECBʼs de Guindos, BoEʼs Pill, Earnings from Moderna.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

APAC stocks were mostly lower as the region took its cue from the losses stateside, where tech underperformed as AI-disruption concerns re-emerged, and logistics/industrials stocks were also pressured after Algorhythm Holdings (RIME) released its AI freight scaling tool.US President Trump said we have to make a deal with Iran and could reach a deal over the next month.US President Trump reiterated he is going to China in April and that Chinese President Xi will visit the US later this year, while he added the relationship with China is very good right now.European equity futures indicate an uneventful cash market open with Euro Stoxx 50 futures down 0.1% after the cash market closed with losses of 0.4% on Thursday.Looking ahead, highlights include German Wholesale Prices (Jan), Swiss CPI (Jan), EZ Prelim Employment (Q4), GDP 2nd Estimate (Q4), US CPI (Jan), Speakers including ECB's de Guindos, BoE's Pill, Earnings from Moderna & NatWest.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a series of significant shifts in the industry, marked by leadership changes, scientific advancements, strategic partnerships, and regulatory challenges.Starting with Sanofi, a notable leadership transition has taken place as Paul Hudson steps down from his role as CEO. Belen Garijo from Merck KGaA has stepped into this pivotal role. Her appointment is part of a broader industry trend toward diversifying leadership, especially with more women leading top-tier pharmaceutical companies. The implications of this shift could be profound for Sanofi, potentially stabilizing its operations and revitalizing its research pipeline. Stakeholders are keenly observing how this new leadership might steer Sanofi through complex market dynamics.In regulatory news, Moderna has encountered a significant hurdle with the FDA declining to review its next-generation mRNA flu vaccine. This decision has sparked an ongoing public dialogue between Moderna and U.S. health regulators, underscoring the complexities involved in navigating regulatory pathways for novel mRNA technologies beyond their initial success with COVID-19 vaccines. The Department of Health and Human Services has supported the FDA's decision, emphasizing the critical importance of meticulous scrutiny when it comes to new vaccine platforms. This development highlights the challenges biotech companies face in ensuring compliance with stringent regulatory standards.Financial updates reveal CSL experiencing a sharp decline in net profits, dropping from $2 billion to $384 million year-over-year. This financial downturn has been linked to strategic missteps or operational inefficiencies within the company, prompting a change in leadership. Such shifts reflect broader challenges faced by companies within the biotech sector as they strive to maintain financial stability amid fluctuating market conditions.In contrast, Alnylam Pharmaceuticals has reported its first profitable year despite underwhelming sales figures for its drug Amvuttra in the ATTR-CM market. This milestone is significant for Alnylam as it demonstrates resilience and the potential to pivot successfully amidst market uncertainties. However, the company will need to remain vigilant about revenue streams and market dynamics moving forward.Turning to advertising strategies, Johnson & Johnson's Tremfya continues to buck industry trends by maintaining a strong presence in television advertising through 2026. This strategy is noteworthy given the general decline in traditional media spending across the industry. J&J's commitment highlights its determination to sustain market share against competitors such as AbbVie's Rinvoq and Skyrizi.On the strategic front, Takeda Pharmaceuticals is consolidating its U.S. operations by reducing its Boston presence. By subleasing over 630,000 square feet of office space, Takeda aims to streamline operations and concentrate resources on key development projects at its new Cambridge hub. This move reflects broader industry trends towards operational efficiency and resource optimization.In clinical advancements, BridgeBio has reached a promising milestone with successful Phase 3 trial results for infigratinib in treating dwarfism. This breakthrough offers new therapeutic options for children affected by this condition and exemplifies ongoing innovations in genetic medicine. The success of this trial positions BridgeBio on a path toward regulatory approval, potentially transforming care for patients with limited treatment options.Agilent has achieved FDA approval for its companion diagnostic test alongside Merck's Keytruda for ovarian cancer treatment. This approval highlights the growing importance of precision medicine in oncology, where tailored treatments based on individual paSupport the show

Los protagonistas del día en EE.UU a análisis de la mano de Ricardo Tomás, asesor del Fondo Multigestión Basalto USA: IPC enero, Moderna, Advance Auto Parts, Chevrom, AirBnb.

It looked like Shopify's stock was headed for a great day when it reported earnings, only for the stock to give up all its gains and then some when management started talking on the conference call. The gang discusses why management's comments had such a profound effect on the stock. Plus, a look at Moderna after the recent FDA approval and stocks on our radar Tyler Crowe, Matt Frankel, and Jon Quast discuss: - The market's sharp reaction to Shopify's earnings - e-commerce in the era of agentic commerce - The FDA's refusal to review Moderna's new flu vaccine - Stocks on our radar Companies discussed: SHOP, AMZN, GOOG, PINS, WMT, MRNA, TREX, CROX, SAFRY Host: Tyler Crowe Guests: Matt Frankel, Jon Quast Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

(February 12, 2026) Key takeaways from Pam Bondi's House hearing. LAPD on course to put drones in the sky as first responders. Thousands of apartments set to take over empty office buildings with new L.A. ordinance. FDA declines to review Moderna flu vaccine.See omnystudio.com/listener for privacy information.

“I do not believe we should be testing to test. We have to know, is this test going to change management and is it going to make a difference,” says pediatric allergist-immunologist Dr. Zachary Rubin. His knack for providing that sort of straightforward guidance explains why Dr. Rubin has become a trusted voice on allergies, asthma, and vaccines for his millions of followers on social media platforms. It's also why we couldn't ask for a better guide for our discussion on the rise in allergies, asthma, and immune-related conditions in children, and how families can navigate the quickly evolving science and rampant misinformation in the space. On this episode of Raise the Line, we also preview Dr. Rubin's new book, All About Allergies, in which he breaks down dozens of conditions and diseases, offering clear explanations and practical treatment options for families. Join host Lindsey Smith for this super informative conversation in which Dr. Rubin shares his thoughts on a wide range of topics including: What's behind the rise in allergic and immune-related conditions.Tips for managing misinformation, myths and misunderstandings. How digital platforms can be leveraged to strengthen public health.How to build back public trust in medicine.Mentioned in this episode:All About Allergies bookBench to Bedside PodcastInstagramTikTokYouTube Channel If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Nine are dead in a tragic school shooting in British Columbia, Canada, Violent clashes erupt in Albania over a corruption scandal, Benjamin Netanyahu meets President Trump to discuss the Iran nuclear talks, the FAA lifts its El Paso, Texas airspace closure, Kenya's foreign minister will visit Russia over reports of a military recruitment scheme, the Colombian President's helicopter is diverted over an alleged shooting threat, a man is questioned and released in the Nancy Guthrie disappearance, the FDA rejects Moderna's mRNA flu vaccine over the trial design, the Pentagon adds ChatGPT to GenAI.mil for 3 million personnel, and Britney Spears sells the rights to her music catalog. Sources: Verity.News

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping the landscape of drug development, regulatory scrutiny, and corporate strategies.At the forefront is Madrigal Pharmaceuticals' strategic acquisition of Ribo Therapeutics' preclinical siRNA programs, valued at $4.4 billion. This move aims to fortify Madrigal's liver disease drug portfolio alongside its promising candidate, resmetirom. By expanding into RNA-based therapies, Madrigal highlights an industry trend focused on gene silencing techniques to target genetic diseases more precisely.Turning to Moderna, it faces a regulatory hurdle as the FDA issued a refusal-to-file letter for its mRNA-based flu vaccine. The regulator's concerns about the trial design, specifically the use of a licensed standard-dose seasonal influenza vaccine as a control arm, emphasize the complexities of advancing mRNA technologies beyond COVID-19 applications. This situation underscores the necessity for meticulous trial designs that align with evolving regulatory standards.In cell therapy, allogeneic CAR-T treatments are gaining attention as companies strive to make these therapies more accessible by using T cells from healthy donors, rather than modifying a patient's cells. Despite technical challenges like graft-versus-host disease and immune rejection, these treatments promise streamlined manufacturing and reduced costs, marking a significant evolution from the pioneering autologous CAR-T success with Emily Whitehead in 2012. Eli Lilly's entry into CAR T-cell therapy through a $2.4 billion acquisition of Orna represents an ambitious expansion into autoimmune therapies. This strategic move exemplifies a broader trend where companies diversify portfolios to include emerging therapeutic modalities promising transformative impacts on patient care.In respiratory medicine, Upstream Bio's phase 2 trial of its TSLP receptor agonist showed encouraging results in reducing asthma exacerbations, comparable to Tezspire. However, falling short of best-case scenarios leaves room for competitors to present more compelling data. This illustrates the competitive nature of asthma treatment development and the ongoing quest for superior therapeutic options.A critical regulatory update arises from the NIH's decision to halt the Xarelto arm of a stroke prevention trial due to safety concerns. This decision highlights the indispensable role of independent monitoring committees in ensuring patient safety and meaningful clinical trial outcomes.On the corporate front, AstraZeneca has articulated an ambitious goal to achieve over 25 blockbuster drugs by 2030 as part of its strategy to reach $80 billion in revenue. This vision underscores the importance of innovation and strategic planning in sustaining growth within an increasingly competitive market.Fujifilm Biotechnologies' completion of its £400 million expansion project in the UK is another notable development, signaling robust investment in antibody production capabilities. This expansion positions Fujifilm as a key player in biopharmaceutical contract manufacturing and underscores the growing demand for flexible production technologies.The biotech sector is also witnessing significant activity with Pelage making strides in addressing hair loss through promising candidate developments. The market's enthusiasm for innovative solutions beyond traditional treatments reflects a broader demand for cutting-edge approaches to longstanding medical challenges.In obesity treatment, Novo Nordisk and Eli Lilly continue to lead with notable advancements. Novo Nordisk's recent developments with its Wegovy pill have been positively received, yet analysts question if this will suffice in maintaining their competitive edge given the dynamic nature of this therapeutic areSupport the show

Unser Partner Scalable Capital ist der einzige Broker, den deine Familie zum Traden braucht. Bei Scalable Capital gibt's nämlich auch Kinderdepots. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Wieder Bilanzprobleme bei Gerresheimer. Keine Probleme bei Schott. Mattel schwach. Cloudflare stark wegen KI. Moderna hat Stress mit FDA. KraftHeinz will ganz bleiben. Warner-Investor will Paramount. Siemens Energy an DAX-Spitze. Fat Finger bei Bithumb.T-Mobile (WKN: A1T7LU) steht für zwei Drittel vom Umsatz der Telekom (WKN: 555750). Darum sind die Zahlen der US-Tochter so wichtig. Wir schauen, wie es auf dem US-Mobilfunkmarkt läuft. Layer2-Netzwerke sollten Ethereum zu schnellem Wachstum helfen. Ausgerechnet Gründer Vitalik Buterin sagt jetzt: Der Plan ergibt keinen Sinn mehr. Diesen Podcast vom 12.02.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

On the DSR Daily for Wednesday, we discuss the Congressional hearing on immigration oversight, the FDA rejecting a Moderna flu vaccine, growing calls for the resignation of Howard Lutnick, and more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Howie Kurtz on the latest in the investigation into the kidnapping of Nancy Guthrie, newly released Epstein files showing President Trump reportedly contacted Palm Beach Police to support their investigation into Jeffrey Epstein, and the FDA's refusing to review Moderna's application for a new mRNA flu vaccine. Learn more about your ad choices. Visit podcastchoices.com/adchoices

AlabamaAn event involving 1819 News CEO is cancelled over threats and safetyAL House Majority Leader Scott Stadhagen to run for ALGOP ChairmanAn illegal alien is under arrest in Mobile for kidnapping of 3 peopleNew EBT cards from AL Dept of Human Resources are now chip enabledState Sales tax holiday coming for severe weather suppliesMobile pastor, Travis Johnson talks about new book and how he learned to stand up for his faithNationalA federal appeals court rules that DHS can end TPS status for migrantsPresident Trump takes on Canada for courting China and ignoring USFL Congresswoman has plans to send the SAVE Act over to Senate for voteFBI releases the warrant document leading to raid of election hub in GAAZ sheriff has person of interest in custody re: kidnapped Nancy GuthrieFDA has rejected Moderna's review request for new mRNA flu vaccine

The F.D.A refused to review Moderna's multi-million-dollar new flu vaccine, in what experts is the latest sign that RFK's Health Department is hostile to vaccines. Plus, concerning news about the effects of sitting and on childhood obesity rates.

On the DSR Daily for Wednesday, we discuss the Congressional hearing on immigration oversight, the FDA rejecting a Moderna flu vaccine, growing calls for the resignation of Howard Lutnick, and more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

On the DSR Daily for Wednesday, we discuss the Congressional hearing on immigration oversight, the FDA rejecting a Moderna flu vaccine, growing calls for the resignation of Howard Lutnick, and more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

The F.D.A refused to review Moderna's multi-million-dollar new flu vaccine, in what experts is the latest sign that RFK's Health Department is hostile to vaccines. Plus, concerning news about the effects of sitting and on childhood obesity rates.

Marc opens with birthday wishes for Sue Thomas and previews a busy hour ahead, including Heritage VP Mary Vogt and Haley Davis on travel. The hour dives into ICE enforcement, highlighting Caroline Levitt's takedown of CBS misreporting illegal alien arrests, and the ongoing discussion of Georgia election irregularities. Mike Gavin joins to provide market updates, discuss grounded flights in El Paso due to security concerns, Moderna's FDA setback, and crypto volatility. Light moments include a humorous segment on new technology measuring gas emissions and sleep and lifestyle tips in “In Other News.” Hashtags: #CarolineLevitt #ICEEnforcement #GeorgiaElection #MarketUpdate #MikeGavin #InOtherNews #MarkCoxMorningShow

The F.D.A refused to review Moderna's multi-million-dollar new flu vaccine, in what experts is the latest sign that RFK's Health Department is hostile to vaccines. Plus, concerning news about the effects of sitting and on childhood obesity rates.

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk about the latest health news. Dr. Marty discusses a study about caffeine and the benefits of it, as well as why the FDA refused to accept Moderna’s application for a new flu vaccine.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's episode, we delve into the dynamic landscape of these industries, exploring ambitious strategic plans, regulatory hurdles, scientific breakthroughs, and emerging trends that are shaping the future of healthcare.Let's begin with AstraZeneca, which has set an ambitious target to achieve $80 billion in revenue by 2030. This goal reflects their intention to bring over 25 blockbuster drugs to market, underscoring a commitment to innovation and expansion in their therapeutic portfolio. The focus on cutting-edge research is not just a strategy for growth but also a sign of the broader industry trend where large pharmaceutical companies pursue high-value targets to strengthen their market positions. AstraZeneca is also making strides in the weight-loss market with its new candidate elecoglipron, undergoing an extensive late-stage program to evaluate its efficacy as a monotherapy and in combination treatments for various indications. This development positions AstraZeneca competitively in the burgeoning sector, offering a novel therapeutic option for obesity management.Meanwhile, CSL Limited is undergoing a leadership transition. CEO Paul McKenzie has stepped down under pressure, and Gordon Naylor has been appointed as interim chief. This change highlights the critical role of strategic leadership in navigating industry challenges and maintaining growth trajectories amidst a rapidly shifting market landscape.In a display of financial success, Novartis reported a record-breaking performance for 2025. This achievement led to a 30% increase in CEO Vas Narasimhan's compensation, reaching $32 million. The company's robust financial health is attributed to advancing innovative treatments targeting unmet medical needs, emphasizing how achieving innovation milestones can significantly enhance corporate valuation and leadership rewards.Incyte is preparing for the patent expiration of its blood cancer drug Jakafi in 2028 by focusing on Opzelura, a topical cream that has witnessed a 33% sales increase from the previous year. With sales reaching $678 million, Opzelura's success highlights Incyte's strategic pivot to diversify its product offerings and mitigate risks associated with patent cliffs. This exemplifies how companies must continuously innovate and adapt to maintain competitive advantages.Moderna has entered into a long-term agreement with Mexico to ensure local mRNA vaccine supply through technology transfer to Laboratorios Liomont. This partnership extends Moderna's global footprint and underscores the critical role of mRNA technology in pandemic preparedness and vaccine accessibility, reinforcing its transformative impact on public health strategies.Regulatory landscapes have also seen notable activity. The FDA issued untitled letters concerning potentially misleading drug advertisements from companies like Novo Nordisk, Argenx, and Sobi. Such actions emphasize regulatory vigilance in marketing practices. Additionally, Lilly's Kinsunla failed to secure approval in Scotland, while Regenxbio faced rejection for its gene therapy for Hunter syndrome. These regulatory hurdles highlight the rigorous oversight pharma companies face and the complex pathways drugs must navigate before market approval.Collaborations within the industry are proving crucial for innovation. Merck's collaboration with Calla Lily Clinical Care aims to enhance delivery systems for vaginal therapeutics. Similarly, Bristol Myers Squibb's partnership with Evinova focuses on integrating AI into clinical development processes. These alliances reflect an industry-wide emphasis on leveraging technology to improve drug delivery efficiency and streamline clinical trial operations.Shifting our focus now to scientific advancements and clinical trial results that aSupport the show

The F.D.A refused to review Moderna's multi-million-dollar new flu vaccine, in what experts is the latest sign that RFK's Health Department is hostile to vaccines. Plus, concerning news about the effects of sitting and on childhood obesity rates.

Firman acuerdo para la producción de vacunas Ecatepec reporta reducción del 53% en delitosUrgen donadores de sangre para paciente en hospital del EdomexMás información en nuestro Podcast

México fabricará la vacuna de Moderna contra Covidinicia primera evaluación a jueces electos por voto popular Siguen las Lluvias y fríos en el norte del país 

When it comes to AI, just about everyone is experiencing some “fear of missing out” right now, says Melissa Reeve. “It's not just executives. It's not just your average individual. It's even people who are writing the code.”Humans are “not equipped to absorb these changes so quickly,” she says.Melissa is the creator of the Hyperadaptive Model and author of Hyperadaptive: Rewiring the Enterprise to Become AI-Native. She spent 25 years as an executive and Agile thought leader, which led to pioneering work in Agile marketing and her role as the first VP of Marketing at Scaled Agile. She also co-founded the Agile Marketing Alliance.In this conversation with Daniel and Peter, Melissa discusses how organizations can shift into a 21st Century model with AI integration.Tune in to learn:What an AI-native organization looks likeWhat most organizations are missing when it comes to AI integrationWhat precedence can teach us about how to integrate AIUsing examples like McDonald's, Unilever, and Moderna, Melissa shows that AI isn't just for programmers–it's a leap forward that can improve organizational operations and work environments for everyone.Drop us an e-mail at podcast@stewartleadership.com.—Listen to The Leadership Growth Podcast!https://open.spotify.com/show/6tYdz1gQAxHIQMeNXtkA3z?si=5cf424f1e2954749https://podcasts.apple.com/us/podcast/the-leadership-growth-podcast/id1726606341—Resources and LinksHyperadaptive: Rewiring the Enterprise to Become AI-Native (IT Revolution link) (Amazon link)“The Five Stages of Becoming AI-Native: The Hyperadaptive Model” (article)Hyperadaptive Solutions websiteMelissa Reeve LinkedIn“The Overlooked Key to Leading Through Chaos,” MIT Sloan Management Review “Sensemaking” Article #leadership #podcast #leadershippodcast #leadershipdevelopment #leadershipcoachingIf you liked this episode, please share it with a friend or colleague, or, better yet, leave a review to help other listeners find our show, and remember to subscribe so you never miss an episode. For more great content or to learn about how Stewart Leadership can help you grow your ability to lead effectively, please visit stewartleadership.com and follow us on LinkedIn, Instagram, and YouTube.

En este episodio de El Brieff, analizamos por qué Natixis desafía al consenso y apuesta por tasas altas en México durante todo 2026. Exploramos la ambiciosa estrategia de Sheinbaum para recuperar la soberanía minera y el histórico acuerdo con Moderna para fabricar vacunas de ARN mensajero. Además: la demanda de BYD contra los aranceles de Trump, el multimillonario plan de inversión de Coppel y el programa de repatriación de capitales del SAT.Recibe gratis nuestro newsletter con las noticias más importantes del día.Si te interesa una mención en El Brieff, escríbenos a arturo@strtgy.ai Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a fascinating array of stories that highlight the scientific advancements, regulatory updates, and strategic maneuvers shaping our industry.Let's begin with Biogen's efforts to breathe new life into its spinal muscular atrophy treatment, Spinraza. In response to declining sales, Biogen is launching a high-dose version in Japan, aiming to enhance therapeutic efficacy and regain market competitiveness. This move underscores the company's strategy to offset projected revenue declines by 2026. The decision to pursue this high-dose version reflects Biogen's commitment to maintaining its foothold in a challenging market landscape where innovation is key to survival.Shifting gears to regulatory news, the FDA, led by Commissioner Marty Makary, has taken a firm stance against the proliferation of illegal copycat drugs. This announcement comes on the heels of Hims & Hers' controversial introduction of a compounded version of Novo Nordisk's obesity drug, Wegovy. The FDA's commitment to protecting intellectual property and patient safety is crucial in an era where health tech firms increasingly challenge traditional pharmaceutical boundaries. Novo Nordisk's aggressive marketing strategy for Wegovy, including a high-profile Super Bowl advertisement, highlights the competitive pressures in this growing market segment and underscores the legal tensions between established pharma giants and emerging tech-driven companies.In an unexpected turn of events, BridgeBio faced a significant setback as Pfizer withdrew its tafamidis patent in Europe. This led to a notable drop in BridgeBio's stock price and raised concerns about earlier generic entries into the ATTR-CM market. Such developments signal potential shifts in market dynamics and pricing strategies that companies must navigate carefully.On the clinical front, Bayer's phase 3 study of asundexian has demonstrated remarkable results—a 26% reduction in stroke risk. This positions Bayer favorably against competitors Bristol Myers Squibb and Johnson & Johnson, setting a new benchmark in the high-stakes anticoagulant market. Innovation continues to be paramount as companies strive for superior clinical outcomes that can significantly impact patient care.Regulatory landscapes are evolving as well, with Gilead's Yescarta receiving clearance for expanded use. These milestones are crucial for broadening therapeutic indications and enhancing patient access, underscoring ongoing efforts to address unmet medical needs while sustaining growth trajectories.Meanwhile, Pfizer-backed Priovant has reported promising mid-stage results for brepocitinib in treating dermatomyositis and other rare skin conditions. As a TYK2/JAK1 inhibitor, brepocitinib exemplifies precision medicine's expanding role in addressing autoimmune disorders through targeted therapies.The IPO scene remains vibrant with Agomab Therapeutics and Spyglass Pharma making substantial entries into Nasdaq, collectively raising $350 million. This influx indicates continued investor confidence in biopharma innovation despite broader economic uncertainties—a testament to the sector's resilience and potential for groundbreaking advancements.Corporate dynamics are also shifting as seen with Moderna's Chief Medical Officer Jacqueline Miller stepping down after a brief tenure. Leadership changes such as these often signal strategic realignments within companies as they adapt to complex regulatory environments and competitive pressures.Summarizing these developments illustrates a dynamic landscape marked by scientific innovation, regulatory vigilance, and strategic marketing initiatives. As companies strive for competitive advantage through new drug formulations and market expansions, they must also navigate legal challenges and regSupport the show

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

On today's HighWire, Former CDC Director Robert Redfield is now saying the quiet part out loud, admitting we were right about mRNA and spike protein. Also, Del Celebrates RFK Jr.'s Announcement of 21 new members of the Interagency Autism Coordinating Committee (IACC), the committee responsible for coordinating the government's autism research and response. This is huge, and Del has the details.Then, we examine Moderna's announcement that it is halting new Phase 3 vaccine trials, citing reduced market incentives under increased federal oversight. What does this decision reveal about safety testing, accountability, and public health priorities?Also, a deep dive into the UK's newly announced AI surveillance system — described by officials as a “panopticon.” We unpack the origins of the term and what it signals about the future of mass surveillance.Plus, as fraud investigations rock Minnesota, autism education providers are facing devastating funding cuts. Jennifer Larson of Holland Center joins Del to explain how legitimate, long-standing programs are now at risk — and how families are paying the price.Guest: Jennifer LarsonBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.